Osteoporosis guidelines

Clinical Reviews in Bone and Mineral Metabolism

Volumn 2, Issue 4, 2004, Pages 315-324

  Roth, Mary ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Clinical practice guidelines; Evidence; Guidelines; Management; Osteoporosis; Practice; Recommendations

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; ESTROGEN; FLUORIDE; GESTAGEN; GLUCOCORTICOID; GROWTH FACTOR; IBANDRONIC ACID; IPRIFLAVONE; PARATHYROID HORMONE[1-34]; PHYTOESTROGEN; PREDNISONE; RALOXIFENE; RISEDRONIC ACID; SALCATONIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SIMVASTATIN; STRONTIUM RANELATE; TESTOSTERONE; TIBOLONE; VITAMIN D; VITAMIN K GROUP; ZOLEDRONIC ACID;

DRUG EFFICACY; ESTROGEN THERAPY; EVIDENCE BASED MEDICINE; HEALTH CARE ORGANIZATION; HORMONAL THERAPY; HUMAN; MEDICAL PRACTICE; OSTEOPOROSIS; POPULATION; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; PROPHYLAXIS; REVIEW; TREATMENT INDICATION;

EID: 26244437545     PISSN: 15348644     EISSN: None     Source Type: Journal    
DOI: 10.1385/BMM:2:4:315     Document Type: Review

References (20)

1. Member Panel. American Association of Clinical Endocrinologists (AACE) 2001 medical guidelines for clinical practice for the prevention and management of postmenopausal osteoporosis. 2001 Endocr Pract 7:293-312.
2. Member Panel. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 ed., with selected updates for 2003. 2003 Endocr Pract 9:544-564.
3. Brown JP, Josse RG. Scientific Advisory Council of the Osteoporosis Society of Canada. 2002 Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. 2002 JAMC 167 (10 Suppl):S1-S34.
4. Member Panel. National Osteoporosis Foundation. 2003 Physician's guide to prevention and treatment of osteoporosis. Available at: http://www.nof.org/ Accessed April 8, 2004.
5. Member Panel. Osteoporosis Prevention, Diagnosis and Therapy. 2001 NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. JAMA 285:785-795.
6. Member Panel. Management of postmenopausal osteoporosis: position statement of the North American Menopause Society. 2002 J Amer Menopause 9:84-101.
7. Member Panel. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. 2001 Update. Arthritis and Rheum 44:1496-1503.
8. Adler RA, Hochberg MC. 2003 Suggested guidelines for evaluation and treatment of glucocorticoid-induced osteoporosis for the Department of Veterans Affairs. Arch Intern Med 163:2619-2624.
9. Member Panel. American Gastroenterological Association medical position statement: osteoporosis in gastrointestinal diseases. 2003 Gastroenterology 124: 791-794.
10. Member Panel. American Gastroenterological Association medical position statement: osteoporosis in hepatic disorders. 2003 Gastroenterology 125:937-940.
11. Osteoporosis Society of Canada. Available at: http://www.osteoporosis.ca Accessed October 1, 2004.
12. Heathcote EJ. 2000 Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines. Hepatology 31:1005-1013.
13. Gallagher JC, Goldgar D. 1990 Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. A randomized controlled study. Ann Intern Med 113:649-655.
14. Tilyard MW, Spears GF, Thomson J, Dovey, S. 1992 Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med 326:357-362.
15. Reid IR, Brown JP, Burckhardt P, et al. 2002 Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346:653-661.
16. Nelson H, Humphrey L, LeBlanc E, et al. 2002 Postmenopausal hormone replacement therapy for the primary prevention of chrome conditions: a summary of the evidence for the US Preventive Services Task Force. Rockville, MD: AHRQ; AHRQ Pub. No. 03-513A. On the AHRQ Web site at: http://www.ahrq.gov/clinic/ 3rduspstf/hrt/hrtsum1.htm.
17. Writing Group for the Women's Health Initiative Investigators. 2002 Risks and benefits of estrogen and progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-333.
18. Anderson GL, Limacher M, Assaf AR, et al. 2004 Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291:1701-1712.
19. Member Panel. Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Institute of Medicine. 1997 Dietary reference intakes: calcium, phosphorous, magnesium, vitamin D, and fluoride. Washington, DC: National Academy Press.
20. Member Panel. National Institutes of Health. NIH Consensus Development Panel on Optimal Calcium Intake. 1994 Optimal calcium intake. JAMA 272:1942-1948.